Mylab Discovery Solutions

Smart or AI In-Vitro Diagnostics Market to Record an Exponential CAGR by 2031 - Exclusive Report by InsightAce Analytic

Retrieved on: 
Wednesday, November 29, 2023
Brain, Research, POC, Conditional sentence, Prevalence, Parkinson's disease, Pathology, Incidence, CDX, Urbanization, Cancer, CE, Infection, COVID-19, Mylab Discovery Solutions, RT, Diagnosis, LRRK2, Growth, NGS, IVD, Hospital, AI, Diabetes, IVDR, Marie Cassidy, Qiagen, Medical device, Pharmaceutical industry

The primary driver of market development is the rising incidence of chronic diseases like cancer, diabetes, and others in the nation.

Key Points: 
  • The primary driver of market development is the rising incidence of chronic diseases like cancer, diabetes, and others in the nation.
  • This will increase the need for in-vitro diagnostics, which is expected to propel market growth throughout the forecast period.
  • Additionally, cutting-edge medical technology advancements, including biosensors, lab-on-a-chip, wearables, and POC diagnostics, are progressively playing a significant role in healthcare.
  • The North America Smart or AI In-Vitro Diagnostics market is expected to record a noteworthy market share in revenue and grow at a high CAGR shortly.

Smart or AI In-Vitro Diagnostics Market to Record an Exponential CAGR by 2031 - Exclusive Report by InsightAce Analytic

Retrieved on: 
Wednesday, November 29, 2023
Brain, Research, POC, Conditional sentence, Prevalence, Parkinson's disease, Pathology, Incidence, CDX, Urbanization, Cancer, CE, Infection, COVID-19, Mylab Discovery Solutions, RT, Diagnosis, LRRK2, Growth, NGS, IVD, Hospital, AI, Diabetes, IVDR, Marie Cassidy, Qiagen, Medical device, Pharmaceutical industry

The primary driver of market development is the rising incidence of chronic diseases like cancer, diabetes, and others in the nation.

Key Points: 
  • The primary driver of market development is the rising incidence of chronic diseases like cancer, diabetes, and others in the nation.
  • This will increase the need for in-vitro diagnostics, which is expected to propel market growth throughout the forecast period.
  • Additionally, cutting-edge medical technology advancements, including biosensors, lab-on-a-chip, wearables, and POC diagnostics, are progressively playing a significant role in healthcare.
  • The North America Smart or AI In-Vitro Diagnostics market is expected to record a noteworthy market share in revenue and grow at a high CAGR shortly.

Patient Discovery Achieves HITRUST Risk-based, 2-year Certification to Manage Risk, Improve Security Posture, and Meet Compliance Requirements

Retrieved on: 
Thursday, June 8, 2023
Health equity, Privacy, Certification, HITRUST, Organization, Discovery, Patient, Risk, Mylab Discovery Solutions, Health, Pharmaceutical industry, Medical device

HITRUST Risk-based, 2-year (r2) Certified status demonstrates that the Patient Discovery platform has met key regulations and industry-defined requirements and is appropriately managing risk.

Key Points: 
  • HITRUST Risk-based, 2-year (r2) Certified status demonstrates that the Patient Discovery platform has met key regulations and industry-defined requirements and is appropriately managing risk.
  • This achievement places Patient Discovery in an elite group of organizations worldwide that have earned this certification.
  • HITRUST certification comes only after the most rigorous security assessment available in the health tech space," said Julie Stern, Chief Technology Officer at Patient Discovery.
  • "Patient Discovery's HITRUST Risk-based, 2-year Certification is evidence that they are at the forefront of industry best practices for information risk management and compliance."

Patient Discovery Partners with AmerisourceBergen for Cancer Care Equity

Retrieved on: 
Thursday, May 11, 2023
Business development, Partnership, Housing, Health, AmerisourceBergen, Health equity, Cancer, Patient, Hospital, Mylab Discovery Solutions, Entrepreneurship, Transport, Food security, Nursing

BOSTON, May 11, 2023 /PRNewswire/ -- Patient Discovery Solutions, a leader in health equity solutions that harness the power of patient-centered technology and real-world data to help achieve better health outcomes, joins global healthcare company AmerisourceBergen's Trusted Vendor Program. The collaboration enables community oncology practices, hospitals, and health systems nationwide access to Patient Discovery's Equitable Care Platform, allowing care providers to proactively identify and address social determinants of health to better inform providers and help improve outcomes for cancer patients.

Key Points: 
  • As a partner, Patient Discovery's Equitable Care Platform will seamlessly integrate within a participating practice's current systems, helping to improve information exchange for delivering equitable care across multiple sites of care.
  • Patient Discovery's mission to merge the patient's life outside the clinical setting with their clinical care path aligns perfectly with AmerisourceBergen's corporate priority to advance health equity.
  • We look forward to bringing our team's passion and the power of our network to utilize the Patient Discovery equitable care platform to advance health equity in a more meaningful way," said Charley Deckers, VP, Business Development and Alliances, Specialty Physician Services at AmerisourceBergen.
  • Moving forward, this new platform will enable care teams to deliver targeted care plans aimed at the whole person, improving the patient experience, and reducing the total cost of care.

Julie Stern joins Patient Discovery as Chief Technology Officer

Retrieved on: 
Tuesday, March 21, 2023
Natural language processing, Prevalence, Engineering, Health equity, CISO, Human, Patient, H1, The Co Founder, Machine learning, Mylab Discovery Solutions, Accolade, CIO, Integration, Nursing

BOSTON, March 21, 2023 /PRNewswire/ -- Patient Discovery Solutions , a leader in equitable care solutions that harness the voice of the patient and the power of real-world data to reduce disparities and achieve better health outcomes for all patients, announced the addition of Julie Stern to the position of Chief Technology Officer.

Key Points: 
  • BOSTON, March 21, 2023 /PRNewswire/ -- Patient Discovery Solutions , a leader in equitable care solutions that harness the voice of the patient and the power of real-world data to reduce disparities and achieve better health outcomes for all patients, announced the addition of Julie Stern to the position of Chief Technology Officer.
  • "We are extremely excited to welcome Julie to Patient Discovery, and we look forward to having her leadership as we accelerate our expansion and deliver actionable technology and data solutions for addressing health equity," said Norm Shore, Chief Executive Officer and Co-Founder of Patient Discovery.
  • Ms. Stern also serves as strategic technical advisor to Integrated VC, as well as several healthcare technology companies including Lumate Health and Outro.
  • "The Patient Discovery equitable care platform is delivering action on a long-recognized problem that the industry has struggled to understand and address.

DnaNudge Forges Strategic Partnership With Mylab Discovery Solutions to Deliver Next-Generation Point-of-Decision Diagnostics for Diabetic Foot Infections

Retrieved on: 
Monday, March 13, 2023
Medical Devices, Health, Diabetes, Genetics, Pharmaceutical, Biotechnology, AMR, Bacteria, Amputation, Death, Alfred E. Mann Institute for Biomedical Engineering, Mellitus, Mylab Discovery Solutions, Risk, DnaNudge, Former, MD, Patient, Imperial College London, Malaria, Diagnosis, PCR, Biomedical engineering, Ulcer, Public, HIV/AIDS, Memorandum of understanding, Regius, COVID-19, Infection, Partnership, Biomedicine, Pharmaceutical industry, Medical device, Wayne Horvitz, Lancet

DnaNudge, the UK-based pioneer of lab-free consumer genetics testing and medical diagnostics solutions, today announces a strategic partnership with India’s leading biotech company Mylab Discovery Solutions to develop next-generation molecular diagnostics for diabetic foot infections and other key health conditions.

Key Points: 
  • DnaNudge, the UK-based pioneer of lab-free consumer genetics testing and medical diagnostics solutions, today announces a strategic partnership with India’s leading biotech company Mylab Discovery Solutions to develop next-generation molecular diagnostics for diabetic foot infections and other key health conditions.
  • The diabetic foot ulcer detection kit – one of the world’s first point-of-decision molecular technology solutions – is expected to be available in India in Q2 2023.
  • Studies have shown that many of the bacteria in foot ulcers are resistant to commonly used antibiotics.
  • Commenting on the MoU, MD of Mylab Discovery Solutions Hasmukh Rawal said: “This partnership marks another milestone in our journey towards making cutting-edge molecular diagnostics available in the world.

Proteros receives minority investment from private equity firm Inflexion

Retrieved on: 
Monday, January 9, 2023
Gesellschaft mit beschränkter Haftung, Negotiation, Biotechnology, Development, Partnership, Strategic business unit, Marketing, Growth, LLP, Mylab Discovery Solutions, Financial services, Cryptocurrency, Protein, Pharma, Dodi Protero, Inflection

MARTINSRIED, Germany and MUNICH, Germany, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Proteros biostructures GmbH , a leading German-based, founder-led contract research organization focused on early-stage drug discovery today announced that it has received a minority investment from Inflexion, a leading middle-market private equity firm investing in high-growth, entrepreneurial businesses, by way of partnership capital funding.

Key Points: 
  • MARTINSRIED, Germany and MUNICH, Germany, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Proteros biostructures GmbH , a leading German-based, founder-led contract research organization focused on early-stage drug discovery today announced that it has received a minority investment from Inflexion, a leading middle-market private equity firm investing in high-growth, entrepreneurial businesses, by way of partnership capital funding.
  • Inflexion is a leading mid-market private equity firm which works in partnership with ambitious management teams of high growth, entrepreneurial businesses to accelerate sustainable growth.
  • Funds advised by Inflexion Private Equity Partners LLP have funds under management of c.£7.1bn.
  • Dr. Torsten Neuefeind, founder and CEO of Proteros, said: “I am excited to have Inflexion on board as a partner.

EQS-News: Proteros receives minority investment from private equity firm Inflexion

Retrieved on: 
Sunday, January 22, 2023
Marketing, Partnership, Gesellschaft mit beschränkter Haftung, Growth, Mylab Discovery Solutions, LLP, Development, Strategic business unit, Negotiation, Biotechnology, Security (finance), Financial services, Cryptocurrency, Inflection, Dodi Protero, Protein, Pharma

Martinsried/Munich, Germany – January 9, 2023 – Proteros biostructures GmbH , a leading German-based, founder-led contract research organization focused on early-stage drug discovery today announced that it has received a minority investment from Inflexion, a leading middle-market private equity firm investing in high-growth, entrepreneurial businesses, by way of partnership capital funding.

Key Points: 
  • Martinsried/Munich, Germany – January 9, 2023 – Proteros biostructures GmbH , a leading German-based, founder-led contract research organization focused on early-stage drug discovery today announced that it has received a minority investment from Inflexion, a leading middle-market private equity firm investing in high-growth, entrepreneurial businesses, by way of partnership capital funding.
  • Inflexion is a leading mid-market private equity firm which works in partnership with ambitious management teams of high growth, entrepreneurial businesses to accelerate sustainable growth.
  • Funds advised by Inflexion Private Equity Partners LLP have funds under management of c.£7.1bn.
  • Dr. Torsten Neuefeind, founder and CEO of Proteros, said: "I am excited to have Inflexion on board as a partner.

Diagnostic Equipment Global Market Report 2022: Featuring Philips Healthcare, Hitachi Medical Systems, Fujifilm Holdings, Siemens Healthcare & GE Healthcare - ResearchAndMarkets.com

Retrieved on: 
Friday, October 7, 2022
Medical Devices, Health, Benchmark, Luminex Corporation, Arthritis, Mylab Discovery Solutions, Growth, Scanners, Diagnosis, Person, DiaSorin, First Nations in Ontario, Coronavirus, Cancer, Technology, Luminex, CT scan, Acquisition, United Nations, Diabetes, Create, List of life sciences, Medical device, Pharmaceutical industry, Marketing, Medical imaging, Biochemistry, Group

The "Diagnostic Equipment Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Diagnostic Equipment Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • The regions covered in diagnostic devices report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.
  • An increase in the geriatric population is expected to propel the growth of the diagnostic devices market going forward.
  • The emergence of routine diagnostic kits is a key trend gaining popularity in the diagnostic devices market.

India Rapid IVD Kits Market Outlook 2022-2027: Rising Awareness of Rapid Diagnosis Amid Pandemic with Growing R&D Investments by Market Players Aided with Government Support - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 22, 2022
Health, Other Health, Health care in Sweden, Adoption, POC, SD, PHC, COVID-19, Ageing, Prevalence, Biosensor, Population, Growth, Abbott, Technology, Mylab Discovery Solutions, House, FAO Major Fishing Areas, Coronavirus, Diagnosis, SC, Hospital, Awareness, CHC, Public health, Conditional sentence, ScS, CAGR, Animal, Vaccine, Consumer electronics, Dipstick

The "India Rapid IVD Kits Market Outlook to FY'2027F" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "India Rapid IVD Kits Market Outlook to FY'2027F" report has been added to ResearchAndMarkets.com's offering.
  • India Rapid IVD Kits market is highly fragmented market with SD Biosensor as the market leader owing to the high sales volume of rapid ivd test kits; followed J. Mitra & Co and Meril Diagnostic as the major local manufacturers in the market.
  • The India Rapid IVD Kits Market also includes other major manufacturers such as Oscar Medicare, Abbott, Mankind Pharma, Angstrom Biotech, Mylab Discovery Solutions and more.
  • India Rapid IVD Kits Market Segmentation:
    Majority of the entities in the India Rapid IVD Kits market are retailers followed by distributers and manufacturers.